Filters applied:
Did You Mean? ?
one result

 

  • Book
    edited by Néstor Gálvez- Jiménez, Hubert H. Fernandez, Alberto J. Espay, Susan H. Fox.
    Digital : Cambridge2016
    1. The pharmacological basis of Parkinson's disease therapy: an overview -- 2. Anticholinergic agents in the management of Parkinson's disease -- 3. Amantadine and antiglutamatergic drugs in the management of Parkinson's disease -- 4. Monoamine oxidase inhibitors in the management of Parkinson's disease -- 5. Oral dopamine agonists in the management of Parkinson's disease -- 6. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease -- 7. Oral and infusion levodopa therapy in the management of Parkinson's disease -- 8. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease -- 9. Experimental pharmacological agents in the management of Parkinson's disease -- 10. Management of autonomic dysfunction in Parkinson's disease -- 11. Management of cognitive impairment in Parkinson's disease -- 12. A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease -- 13. Management of disease-related behavioral disturbances in Parkinson's disease -- 14. Management of disease-related behavioral disturbances in Parkinson's disease -- 15. Management of sleep disorders in Parkinson's disease -- 16. Management of pain and neuromuscular complications in Parkinson's disease -- 17. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease -- 18. Deep-brain stimulation of the globus pallidus internus in the management of Parkinson's disease -- 19. Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson's disease -- 20. Deep-brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease -- 21. Emerging targets and other stimulation-related procedures in the management of Parkinson's disease -- 22. Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease -- 23. Functional imaging markers as outcome measures in clinical trials for Parkinson's disease -- 24. Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease -- 25. Lessons learned: neuroprotective trials in Parkinson's disease -- 26. Lessons learned: symptomatic trials in early Parkinson's disease -- 27. Controversy: globus pallidus internus versus subthalamic nucleus deep-brain stimulation in the management of Parkinson's disease -- 28. Controversy: ablative surgery vs. deep-brain stimulation in the management of Parkinson's disease -- 29. Controversy: midstage vs. advanced-stage deep-brain stimulation in the management of Parkinson's disease -- 30. Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease -- 31. Lessons and challenges of trials for other nonmotor complications of Parkinson's disease -- 32. Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease.